This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Dynavax Options Trade for Heplisav FDA Approval Decision

Stocks in this article: DVAX

NEW YORK ( TheStreet) -- Dynavax (DVAX - Get Report) has an FDA approval decision date of Feb. 24 for its hepatitis B vaccine Heplisav. Last November, Dynavax shares were cut in half due to a mixed vote from an FDA advisory panel. I wrote about this panel and paired it with an interesting option trade.

Since then, Dynavax shares have climbed to $3, a 40% increase, yet still trade under last year's highs in the $5 range. If FDA approves Heplisav, I expect the shares to trade at least above $4. To trade the FDA approval from a bullish perspective, a potentially profitable options trade using is to do the following:

Buy 10 MAR 2.50 strike Calls at $1.00 = $1,000 Debit

This opening trade is fairly straight forward as we are simply buying in-the-money Calls. The total risk at this point is the amount paid for the Calls, or in the example, $1,000. I chose the Calls over buying the shares outright simply due to risk management. If the company receives a Complete Response Letter (i.e. the FDA does not approve Heplisav), I expect the shares to drop below $1.50. (Dynavax has about 75 cents per share in cash. Buying the shares could represent more risk as the downside of owning 1,000 shares at $3.00 could expose me to at least $500 in additional losses compared to the losses on the Calls, which is capped at the amount of the debit, or $1,000.

This trade includes a lot of optionality, or ways to adjust the original position due to changes in the share price. If the shares run up into Feb. 24 decision date, I maintain the option to sell the Calls at a profit. An alternative, risk-reducing trade that maintains some upside under this scenario would be to do the following:

Assume a pre-FDA decision run up in Dynavax to $3.75 per share -- not overly aggressive as the shares recently traded as high as $3.50.

(Still holding) 10 MAR 2.50 Calls at $1.00 = $1,000
Sell 20 MAR 5 strike Calls at $0.50 = $(1,000)
Buy 10 MAR 6 strike Calls at $0.30 = $300
(Adjusted P&L) = $300 Debit

Here's the Risk P&L Diagram for this trade:

With this adjustment, total risk in the position is decreased from $1,000 to $300. Despite this reduction in risk, we still maintain upside in the position. Maximum profit is $2,200 if the shares trade to $5 by expiration. If they trade at any point above $6, maximum profit is $1,200. If DVAX receives a Conplete Response Letter and the shares crash to below $1.50, we only lose $300.

Pelz has no position in Dynavax.

To learn more about using options to trade biotech catalysts, check out Tony Pelz's book, The Biotech Trader Handbook.

Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of PelzOptions.com. Pelz currently resides in Denver, Colorado where he trades for his own account.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs